Your browser doesn't support javascript.
loading
Developing a patient decision aid for women aged 70 and older with early stage, estrogen receptor positive, HER2 negative, breast cancer.
Schonberg, Mara A; Freedman, Rachel A; Recht, Abram R; Jacobson, Alicia R; Aliberti, Gianna M; Karamourtopoulos, Maria; Nakhlis, Faina; McCarthy, Ellen P; Pories, Susan E; Sharma, Ranja; Dominici, Laura S.
Affiliation
  • Schonberg MA; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States of America. Electronic address: mschonbe@bidmc.harvard.edu.
  • Freedman RA; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States of America.
  • Recht AR; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States of America.
  • Jacobson AR; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States of America.
  • Aliberti GM; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States of America.
  • Karamourtopoulos M; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States of America.
  • Nakhlis F; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States of America.
  • McCarthy EP; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States of America.
  • Pories SE; Mount Auburn Hospital, 300 Mount Auburn Street, Cambridge, MA, United States of America.
  • Sharma R; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States of America.
  • Dominici LS; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States of America.
J Geriatr Oncol ; 10(6): 980-986, 2019 11.
Article in En | MEDLINE | ID: mdl-31130442
OBJECTIVES: Since women ≥70 years with early stage, estrogen receptor positive (ER+), HER2 negative breast cancer face several preference-sensitive treatment decisions, the investigative team aimed to develop a pamphlet decision aid (DA) for such women. MATERIALS AND METHODS: The content of the DA was informed by literature review, international criteria, and expert feedback, and includes information on benefits and risks of lumpectomy versus mastectomy, lymph node surgery, radiotherapy after lumpectomy, and endocrine therapy. It considers women's overall health and was written using low literacy principles. Women from two Boston-based hospitals who were diagnosed in the past 6-24 months were recruited to provide feedback on the DA and its acceptability. The DA was iteratively revised based on their qualitative input. RESULTS: Of 48 eligible women contacted, 35 (73%) agreed to participate. Their mean age was 74.3 years; 33 (94%) were non-Hispanic white; and 24 (67%) were college graduates. Overall, 26 (74%) thought the length of the DA was just right, 29 (83%) thought all or most of the information was clear, 32 (91%) found the DA helpful, and 33 (94%) would recommend it. In open ended comments, participants noted that the DA was clear, well-organized, and would help women prepare for and participate in treatment decision-making. CONCLUSIONS: The investigative team developed a novel breast cancer treatment DA that is acceptable to women ≥70 years with a history of ER+, HER2-, early stage breast cancer. Next, the DA's efficacy needs to be tested with diverse older women newly diagnosed with breast cancer.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Decision Support Techniques Type of study: Prognostic_studies / Qualitative_research Limits: Aged / Female / Humans Language: En Journal: J Geriatr Oncol Year: 2019 Document type: Article Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Decision Support Techniques Type of study: Prognostic_studies / Qualitative_research Limits: Aged / Female / Humans Language: En Journal: J Geriatr Oncol Year: 2019 Document type: Article Country of publication: